<DOC>
	<DOCNO>NCT01717573</DOCNO>
	<brief_summary>During primary PCI , stent deployment post-dilatation associate no-reflow . The mechanisms reflow include distal embolization thrombus , enhance thrombus formation vascular spasm . No reflow associate risk factor prolong duration ischaemia , heavy thrombus burden , persistent ST elevation long stent length . ACTIVE HYPOTHESIS : normal antegrade flow re-established initial aspiration thrombectomy and/or balloon angioplasty begin primary PCI , compare usual care direct stenting , strategy defer stenting 4 -16 hour permit beneficial effect normalize coronary blood flow anti-thrombotic therapy reduce incidence reflow at-risk STEMI patient . DESIGN : In consecutive STEMI patient risk factor reflow give informed consent , normal flow establish ( TIMI 3 ) initial aspiration thrombectomy and/or balloon angioplasty , participant randomize deferred stenting usual care direct stenting . All patient receive dual anti-platelet therapy . Patients randomize deferred stenting receive intravenous glycoprotein IIbIIIa inhibitor anti-coagulation low molecular weight heparin . Patients screen eligible randomize prospectively entered registry . Study assessments feasibility , safety efficacy prospectively perform . An independent clinical event committee review serious adverse event . Study endpoint subject core laboratory analysis . The study intend inform design large multicentre clinical trial .</brief_summary>
	<brief_title>Deferred Stent Trial STEMI</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Rescue PCI Prolonged ischaemic time ( &gt; 12hours ) Previous MI Age &gt; 65 Occluded artery ( TIMI 0/1 ) initial angiography Thrombus burden ( TIMI grade 2+ ) Long plaque/ stent length ( &gt; 24 mm ) Severe coronary artery disease ( e.g calcify artery ) Small reference vessel diameter ( &lt; 2.5 mm ) Persistent STelevation ( &gt; 50 % ) follow reperfusion Index microvascular resistance ( IMR ) &gt; 40 Absence normal coronary flow ( TIMI 3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>STEMI</keyword>
	<keyword>No-reflow</keyword>
	<keyword>Primary percutaneous intervention</keyword>
	<keyword>Deferred stenting</keyword>
</DOC>